ID | 68737 |
フルテキストURL | |
著者 |
Haratake, Tomoka
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Nishimura, Midori Filiz
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Nishikori, Asami
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Gonzalez, Michael V.
Center for Cytokine Storm Treatment and Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania
Ennishi, Daisuke
Center for Comprehensive Genomic Medicine, Okayama University Hospital
Lai, You Cheng
Department of Medical Biotechnology and Laboratory Science, Chang Gung University
Ochi, Sayaka
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Tsunoda, Manaka
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
Fajgenbaum, David C.
Center for Cytokine Storm Treatment and Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania
van Rhee, Frits
Center for Cytokine Storm Treatment and Laboratory, Department of Medicine, Perelman School of Medicine, University of Pennsylvania
Momose, Shuji
Department of Pathology, Saitama Medical Center, Saitama Medical University
Sato, Yasuharu
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences
ORCID
Kaken ID
researchmap
|
抄録 | Idiopathic multicentric Castleman disease is a rare lymphoproliferative disorder that is clinically classified into idiopathic plasmacytic lymphadenopathy (IPL); thrombocytopenia, anasarca, fever, reticulin fibrosis, and organomegaly (TAFRO); and not otherwise specified (NOS). Although each subtype shows varying degrees of hypervascularity, no statistical data on the degree of vascularization have been reported. Additionally, the mechanisms underlying vascularization in each clinical subtype are poorly understood. Here, we aimed to clarify these mechanisms by evaluating the histopathological characteristics of each clinical subtype across 37 patients and performing a whole-transcriptome analysis focusing on angiogenesis-related gene expression. Histologically, TAFRO and NOS exhibited a significantly higher degree of vascularization than IPL (IPL vs TAFRO, P < .001; IPL vs NOS, P = .002). In addition, the germinal centers (GCs) were significantly more atrophic in TAFRO than in IPL. In TAFRO and NOS, “whirlpool vessels” in GCs were seen in most cases (TAFRO, 9/9, 100%; NOS, 6/8, 75%) but not in IPL (IPL vs TAFRO, P < .001; IPL vs NOS, P = .007). Likewise, immunostaining for Ets-related gene revealed higher levels in endothelial cells of GCs in TAFRO than in IPL (P = .014), and TAFRO and NOS were associated with a significantly higher number of endothelial cells in interfollicular areas compared with that in IPL (TAFRO vs IPL, P < .001; NOS vs IPL, P = .002). Gene expression analysis revealed that the PI3K–Akt signaling pathway was significantly enriched in the TAFRO and NOS (TAFRO/NOS) groups. This pathway, which may be activated by vascular endothelial growth factor A and some integrins, is known to affect angiogenesis by increasing vascular permeability, which may explain the clinical manifestations of anasarca and/or fluid retention in TAFRO/NOS. These results suggest that the PI3K–Akt pathway plays an important role in the pathogenesis of TAFRO/NOS.
|
キーワード | idiopathic multicentric Castleman disease
integrin subunit alpha 5
PI3K–Akt signaling pathway
platelet-derived growth factor receptor beta
vascular endothelial growth factor A
vascularity
|
発行日 | 2025-08
|
出版物タイトル |
Modern Pathology
|
巻 | 38巻
|
号 | 8号
|
出版者 | Elsevier BV
|
開始ページ | 100782
|
ISSN | 0893-3952
|
NCID | AA1067307X
|
資料タイプ |
学術雑誌論文
|
言語 |
英語
|
OAI-PMH Set |
岡山大学
|
著作権者 | © 2025 THE AUTHORS.
|
論文のバージョン | publisher
|
PubMed ID | |
DOI | |
Web of Science KeyUT | |
関連URL | isVersionOf https://doi.org/10.1016/j.modpat.2025.100782
|
ライセンス | http://creativecommons.org/licenses/by/4.0/
|
助成機関名 |
Japan Society for the Promotion of Science
Ministry of Health, Labour and Welfare
Japan Agency for Medical Research and Development
|
助成番号 | JP23K14476
JP24KK0172
JP25K02476
JPMH23FC1025
JP24ek0109589
|